AVADEL PHARMACEUTICALS PLC
AVDLHealthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $169.1M | $28.0M | $0 | $0 | $22.3M | $59.2M |
| Operating income | −$42.4M | −$137.8M | −$98.6M | −$85.5M | $5.8M | −$24.1M |
| Net income | −$48.8M | −$160.3M | −$137.5M | −$77.3M | $7.0M | −$33.2M |
| Total assets | $164.2M | $164.7M | $132.8M | $247.3M | $311.6M | $151.4M |
| Total liabilities | $90.4M | $77.0M | $153.9M | $169.0M | $149.4M | $180.6M |
| Equity | $73.8M | $87.7M | −$21.1M | $78.2M | $162.3M | −$29.2M |
| EPS (diluted) | $-0.51 | $-2.00 | $-2.29 | $-1.32 | $0.13 | $-0.89 |
| Shares out. | 90.6M | 64.5M | 59.0M | 58.5M | 46.4M | 37.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −25.1%
- Net margin
- −28.9%
- Return on equity
- −66.1%
- Return on assets
- −29.7%
- Return on capital (ROCE)
- −36.7%
- Liabilities / assets
- 55.0%
- Debt / equity
- 1.22×
- Book value / share
- $0.82
- Revenue growth (YoY)
- 504.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -13.23distress
- Accruals / assets
- −1.2%clean
- Beneish M-Score
- 1.57elevated
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 16, 2017
- NT 10-Qmissed a reporting deadline ↗Nov 9, 2016
- NT 10-Qmissed a reporting deadline ↗Aug 10, 2016
- NT 10-Kmissed a reporting deadline ↗Feb 29, 2016
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Janus Henderson Group PlcPassive (13G)Feb 17, 2026
- Two Seas Capital LpPassive (13G)Feb 17, 2026
- Brandes Investment Partners, LpPassive (13G)Feb 12, 2026
- Gendell Jeffrey LPassive (13G)Feb 6, 2026
- Vanguard Group IncPassive (13G)Jul 29, 2025
- Blackrock, Inc.Passive (13G)Jul 16, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Jan 30, 2026 | 2.3M | 2.5 | -36.0% |
| Jan 15, 2026 | 3.6M | 1.7 | +32.1% |
| Dec 31, 2025 | 2.7M | 2.4 | -6.1% |
| Dec 15, 2025 | 2.9M | 1.5 | -25.6% |
| Nov 28, 2025 | 3.9M | 1.5 | -41.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Regulation FD disclosureFeb 12, 2026
- Other material eventJan 20, 2026
- Shareholder vote · Other material eventJan 12, 2026
- Regulation FD disclosure · Other material eventDec 18, 2025
- Other material eventDec 9, 2025
- Entered a material agreement · Regulation FD disclosureNov 19, 2025
- Other material eventNov 17, 2025
- Other material eventNov 14, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GFeb 23, 2026
- 4PRIMARY DOCUMENTFeb 18, 2026
- 3PRIMARY DOCUMENTFeb 18, 2026
- SCHEDULE 13G/AFeb 17, 2026
- SCHEDULE 13G/AFeb 17, 2026
- EFFECTFeb 13, 2026
- EFFECTFeb 13, 2026
- EFFECTFeb 13, 2026
- EFFECTFeb 13, 2026
- 4OWNERSHIP DOCUMENTFeb 12, 2026
- 4OWNERSHIP DOCUMENTFeb 12, 2026
- 4OWNERSHIP DOCUMENTFeb 12, 2026
- 4OWNERSHIP DOCUMENTFeb 12, 2026
- 4OWNERSHIP DOCUMENTFeb 12, 2026
- 4OWNERSHIP DOCUMENTFeb 12, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.